Adjunctive, Low-Dose tPA in Primary PCI for STEMI
common.study.values.description
“Adjunctive, Low-dose tPA in Primary PCI for STEMI”
STRIVE will evaluate the use of adjunctive, low-dose intracoronary tissue plasminogen activator during primary percutaneous coronary intervention (PCI) for patients with ST elevation myocardial infarction (STEMI) in reducing the incidence of post-procedural myocardial blush (MBG) grade 0/1 or distal embolization.
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods
common.study.methods.has-drugs-yes
common.study.methods.is-healthy-yes
Drug - tissue plasminogen activator
Recombinant tPA is a fibrin-specific 2nd generation plasminogen activator and thrombolytic drug.
Saline
Placebo
participant.views.study.view.additional
participant.views.study.view.scientific-title
Adjunctive, Low-dose Intracoronary Recombinant Tissue Plasminogen Activator (tPA) Versus Placebo for Primary PCI in Patients With ST-segment Elevation Myocardial Infarction
common.study.values.clinical-trial-id
NCT03335839
participant.views.study.view.id
Pe9K4b
